Medicare Advantage: Rules On Formularies, PPOs Raise Concerns

Why This Topic Matters

These rulemaking details affect how Medicare Advantage and prescription drug plans are structured, how beneficiaries obtain access to covered medications, and how plans prepare for operational compliance. Understanding the issues helps stakeholders anticipate coverage administration changes and monitor CMS policy direction.

Article Sections

1. Formulary oversight and appeals concerns

   Discusses CMS rulemaking questions related to formulary standards, beneficiary access to non-formulary drugs, and the general structure of appeals oversight. It also notes stakeholder concern about how plan drug coverage policies may be evaluated.

2. Model formulary and drug-class concerns

   Summarizes discussion of the proposed model formulary and concerns raised by advocacy groups and lawmakers about how drug classes are organized. The section focuses on broad concerns about coverage design and potential discrimination issues.

3. Geographic regions for Medicare PPOs and drug plans

   Covers uncertainty about how CMS will define service regions for new Medicare PPOs and drug-only plans. It includes comments from lawmakers, insurers, and health plans about possible region structures and implementation timing.

4. GAO review of CMS PPO demonstration project

   Notes a forthcoming Government Accountability Office analysis of CMS's PPO demonstration project and the related debate over the agency's authority in promoting PPO participation.